Search

Displaying results 2441 - 2450 of 8517 in total
  1. Drug

    Tiludronic acid

    go.drugbank.com/drugs/DB01133
    ApprovedVet approvedWithdrawn

    [A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]

  2. Drug

    AZD-8330

    go.drugbank.com/drugs/DB06061
    Investigational

    AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.

  3. Drug

    Velmanase alfa

    go.drugbank.com/drugs/DB12374
    ApprovedInvestigational

    [L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment … Velmanase alfa has an amino acid sequence of the monomeric protein identical to the naturally occurring human alpha-mannosidase.

  4. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.

  5. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.

  6. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L7123] Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at

  7. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  8. Drug

    Aceclofenac

    go.drugbank.com/drugs/DB06736
    Approved

    Aceclofenac belongs to BCS Class II as it possesses poor aqueous solubility [A19667]. … In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug.

  9. Drug

    Silibinin

    go.drugbank.com/drugs/DB09298
    Investigational

    Silibinin is presented as a mixture of two diastereomers, silybin A and silybin B, which are found in an approximately equimolar ratio. … Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins.

  10. Drug

    Oseltamivir

    go.drugbank.com/drugs/DB00198
    ApprovedInvestigational

    effect on hospitalizations, and that there was no evidence for any reductions in complications of influenza such as pneumonia. … Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B.